US FDA approves new oral drug for rare genetic disorder phenylketonuria
The US Food and Drug Administration has approved PTC Therapeutics’ oral drug to treat a rare inherited metabolic disorder that prevents the body from properly breaking down certain amino acids, the company said on Monday. The approval allows PTC to expand its revenue base as its top-selling Duchenne muscular dystrophy therapies, Translarna and Emflaza, face…